Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00573989 · OUTCOME

Change in Quality of Life- FACT H&N

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer · Source last updated 2019-01-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
units on a scale
Interval / dispersion
Standard Deviation
Time frame
baseline and 12 months

What was measured

The Functional Assessment of Cancer Therapy-Head and Neck (FACT H\&N) consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for head and neck related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain. Score range is 0-156. Higher scores denotes better outcomes

Analysis population: Data not collected for all participants at 12 months. Data corresponds to Phase II patients.

Groups in this outcome

Erlotinib

Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Erlotinib10

Reported measurements

baseline

Analysis denominator · Participants

GroupSource count
Erlotinib10
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib84.878.19Not reportedNot reportedNot reported
12 months

Analysis denominator · Participants

GroupSource count
Erlotinib3
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Erlotinib88.6118.64Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.19
        value
        84.87
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        18.64
        value
        88.61
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      units
      Participants
    title
    12 months
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
The Functional Assessment of Cancer Therapy-Head and Neck (FACT H\&N) consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for head and neck related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain. Score range is 0-156. Higher scores denotes better outcomes
dispersion Type
Standard Deviation
groups
  1. description
    Erlotinib erlotinib hydrochloride pemetrexed disodium quality-of-life assessment intensity-modulated radiation therapy
    id
    OG000
    title
    Erlotinib
param Type
MEAN
population Description
Data not collected for all participants at 12 months. Data corresponds to Phase II patients.
reporting Status
POSTED
time Frame
baseline and 12 months
title
Change in Quality of Life- FACT H&N
type
SECONDARY
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice